"The recent decision by Sanofi-Aventis to withdraw its FDA application for the anti-obesity drug rimonabant, marketed as Acomplia, highlights the need for an effective pharmaceutical treatment for obesity," says Patrick Driscoll, President of MedMarket Diligence. "While developers in the market for device and other products to treat clinical obesity are working aggressively, it is clear that an effective pharmaceutical treatment will hold tremendous potential to compete with all treatment types."
The obesity treatment market worldwide is set to grow enormously, and will reach 6.4 billion by 2015. This includes prescription drugs for weight loss and maintenance; devices used in bariatric surgery and follow-up; and the predicted sales of drugs and devices with anticipated launch dates through 2015
The MedMarket Diligence report on the "Worldwide Market for the Clinical Management of Obesity" describes the clinical trends in the management of the obese, the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy. The report provides a current and forecast market for these products in the U.S., Europe and Rest of World, and profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.
The report is described, with preliminary table of contents, at
Drugs and Devices in the Clinical Management of Obesity Worldwide


